Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.
Alejandro Falcón GonzalezJosefina Cruz JuradoElisenda Llabrés ValentiRocío Urbano CuberoMaria Carmen Álamo de la GalaMaría Antonia Martínez GuisadoRocío Álvarez AmbiteCarlos José Rodríguez GonzálezMarta Amérigo GóngoraLourdes Rodríguez PérezPilar López ÁlvarezPedro Sánchez RoviraEncarnación González FloresFernando Henao CarrascoJuan Bayo CaleroMaría Valero ArbizuAlicia Quílez CutillasJavier Salvador BoffilEloísa Rubio PérezManuel Ruiz-BorregoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
Keyphrases
- epidermal growth factor receptor
- early stage
- metastatic breast cancer
- locally advanced
- positive breast cancer
- lymph node
- rectal cancer
- tyrosine kinase
- computed tomography
- squamous cell carcinoma
- neoadjuvant chemotherapy
- sentinel lymph node
- contrast enhanced
- magnetic resonance imaging
- dual energy
- combination therapy
- replacement therapy
- pet ct